Loading...
•
Sep 28, 2024
Charles River Labs Q3 2024 Earnings Report
Charles River Labs' third quarter performance in 2024 saw a slight revenue decrease, but exceeded prior outlook due to stable demand indicators.
Key Takeaways
Charles River Laboratories reported a revenue of $1.01 billion for Q3 2024, a 1.6% decrease compared to Q3 2023. GAAP EPS was $1.33, while non-GAAP EPS was $2.59. The company is navigating a challenging period with biopharmaceutical clients reducing spending, but biotech funding has improved, showing early signs of stabilization.
Third-quarter revenue was $1.01 billion, a 1.6% decrease year-over-year.
GAAP earnings per share were $1.33, and non-GAAP earnings per share were $2.59.
The GAAP operating margin decreased to 11.6% from 14.8% in the third quarter of 2023.
The company repurchased 500,000 shares during the third quarter of 2024 for a total of $100.7 million.
Charles River Labs
Charles River Labs
Charles River Labs Revenue by Segment
Revenue by Segment
Research Models and Services Revenue
CapyFin.comDiscovery and Safety Assessment Revenue
CapyFin.comManufacturing Solutions Revenue
CapyFin.com Forward Guidance
The company is updating its financial guidance for 2024. Revenue and non-GAAP earnings per share guidance have been narrowed and slightly raised from the midpoint of the previous ranges to principally reflect the third-quarter financial performance, which exceeded the Company's prior outlook. In addition, GAAP earnings per share guidance has been reduced due primarily to increased charges related to the Company's additional restructuring actions.
Positive Outlook
- Revenue growth, reported between -3.0% and -2.0%.
- Impact of divestitures/acquisitions, net ~ (0.5)%.
- Favorable/unfavorable impact of foreign exchange ~ (0.5)%.
- Revenue growth, organic between -4.0% and -3.0%.
- Non-GAAP EPS estimate between $10.10 and $10.30.
Challenges Ahead
- GAAP EPS estimate between $5.30 and $5.50.
- Acquisition-related amortization ~$2.50.
- Acquisition and integration-related adjustments ~$0.35.
- Costs associated with restructuring actions ~$1.50.
- Certain venture capital and other strategic investment losses/(gains), net ($0.17).
Revenue & Expenses
Visualization of income flow from segment revenue to net income